General information
| Name: Danijel |
| Surname: Kikelj |
| E-mail: Danijel.kikelj@ffa.uni-lj.si |
| Cell phone number with international prefix: +386-31-504-268 |
| Country: Slovenia |
| Affiliation: University of Ljubljana, Faculty of Pharmacy, Slovenia |
| Gender: F □ M x |
| Year of the PhD title: 1988 |
| Personal web page: http://www.ffa.uni-lj.si/en/faculty/employees/oseba/kikelj-danijel/ |
| Previous COST participation: No □ Yes x |
List of 10 selected publications within last 5 years
| 1. TOMAŠIČ, Tihomir et al., Structure-based design of a new series of D-Glutamic acid-based inhibitors of bacterial UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase (MurD). Journal of medicinal chemistry, 2011, vol. 54, 4600-4610. |
| 2. ZIDAR, Nace et al., New 5-benzylidenethiazolidin-4-one inhibitors of bacterial MurD ligase: design, synthesis, crystal structures, and biological evaluation. European Journal of Medicinal Chemistry, 2011, vol. 465512-5523. |
| 3. TOMAŠIČ, Tihomir et al., Virtual screening for potential inhibitors of bacterial MurC and MurD ligases. Journal of molecular modeling, 2012, vol. 18, 1063-1072. |
| 4. ILIĆ, Miloš et al., Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold. European Journal of Medicinal Chemistry, 2012, vol. 50, 255-263 |
| 5. TOMAŠIČ, Tihomir et al., Dual inhibitor of MurD and MurE ligases from Escherichia coli and Staphylococcus aureus. ACS Medicinal Chemistry Letters, 2012, vol. 3, 626-630. |
| 6. TRSTENJAK, Uroš et al., Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores. European Journal of Medicinal Chemistry, 2013, vol. 64, 302-313. |
| 7. ILIĆ, Miloš et al., Towards dual antithrombotic compounds – Balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism. European Journal of Medicinal Chemistry, 2013, vol. 62, 329-340. |
| 8. TRSTENJAK, Uroš et al., Transformation of selective factor Xa inhibitor rivaroxaban to a dual factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety. MedChemComm, 2014, vol. 5, 197-202. |
| 9. ZIDAR, Nace et al., N-phenyl-4,5-dibromopyrrolamides and N-phenylindolamides as ATP competitive DNA gyrase B inhibitors: design, synthesis, and evaluation. Journal of medicinal chemistry, 2015, vol. 58, 6179-6194 |
| 10. TOMAŠIČ, Tihomir et al., Discovery of 4,5,6,7-tetrahydrobenzo[1, 2-d]thiazoles as novel DNA gyrase inhibitors targeting the ATP-binding site. Journal of medicinal chemistry, 2015, vol. 58, 5501-521. |
Main skills and expertise (up to 5)
| 1. drug design and synthesis |
| 2. peptidomimetics |
| 3. multitarget ligands |
| 4. antibacterial compounds, gyrase B and topoisomerase IV inhibitors |
| 5. dual antithrombotic compounds |
Main equipment/facilities available in the participants’ lab (up to 5)
| 1. modern equipment and facilities for organic synhesis |
| 2. up-to-date molecular modeling equipment |
| 3. NMR (400 MHz) |
| 4. ITC apparatus |
| 5. equipment for enzymatic assays |
Short personal activity proposal for the COST Action CA15135 (max 1000 characters)
|
Design, synthesis and evaluation of multitarget ligands targeting gyrase B, topoisomerase IV and Hsp90
|
Work Group preference: score from 1 (preferred) to 4 (not preferred)
| Work Group of the CA15135 COST Action | Score |
| WG1: Development of new chemical entities | 1 |
| WG2: Selection of biological targets and assessment of biological data | 3 |
| WG3: Development of chemical databases | 4 |
| WG4: Development of Computational methods for multiple ligand design and discovery | 2 |
